ATE128359T1 - Behandlung von diabetes mellitus typ 2. - Google Patents

Behandlung von diabetes mellitus typ 2.

Info

Publication number
ATE128359T1
ATE128359T1 AT89901802T AT89901802T ATE128359T1 AT E128359 T1 ATE128359 T1 AT E128359T1 AT 89901802 T AT89901802 T AT 89901802T AT 89901802 T AT89901802 T AT 89901802T AT E128359 T1 ATE128359 T1 AT E128359T1
Authority
AT
Austria
Prior art keywords
amylin
peptides
methods
diabetes
treatment
Prior art date
Application number
AT89901802T
Other languages
English (en)
Inventor
Garth James Smith Cooper
Howard E Greene
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE128359T1 publication Critical patent/ATE128359T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT89901802T 1988-01-11 1989-01-11 Behandlung von diabetes mellitus typ 2. ATE128359T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14244788A 1988-01-11 1988-01-11

Publications (1)

Publication Number Publication Date
ATE128359T1 true ATE128359T1 (de) 1995-10-15

Family

ID=22499881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89901802T ATE128359T1 (de) 1988-01-11 1989-01-11 Behandlung von diabetes mellitus typ 2.

Country Status (8)

Country Link
EP (1) EP0348490B1 (de)
JP (1) JPH10267914A (de)
AT (1) ATE128359T1 (de)
AU (1) AU631112B2 (de)
DE (1) DE68924372T2 (de)
DK (1) DK443889A (de)
FI (1) FI894255A7 (de)
WO (1) WO1989006135A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0408294B1 (de) * 1989-07-10 1995-09-20 Amylin Pharmaceuticals, Inc. Verwendung eines Amylinantagonisten zur Herstellung eines Artzneimittels zur Behandlung von Fettsucht und essentieller Hypertonie und damit zusammenhängenden Krankheiten
AU8083591A (en) * 1990-06-08 1991-12-31 Symbicom Aktiebolag Therapy and prophylaxis of autoimmune diseases
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
WO1992015015A1 (en) * 1991-02-25 1992-09-03 Zymogenetic, Inc. Methods for detecting galanin antagonists
US5756460A (en) * 1991-03-06 1998-05-26 Garvan Institute Of Medical Research Human galanin, CDNA clones encoding human galanin and a method of producing human galanin
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP0503827A1 (de) * 1991-03-15 1992-09-16 Pfizer Inc. Verwendung von Amylin und Calcitonin-Genverwandten Peptiden und Antagonisten davon
GB9113011D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Novel treatment and compositions
GB9113038D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Novel treatment and compositions
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ATE205854T1 (de) * 1991-11-19 2001-10-15 Amylin Pharmaceuticals Inc Peptide als amylin-agonisten und ihre verwendung
EP0594843B1 (de) * 1992-05-15 2004-11-03 Amylin Pharmaceuticals, Inc. Antikörper-testbesteck zur bestimmung von amylin
JPH07506114A (ja) * 1992-08-06 1995-07-06 ファイザー・インコーポレーテッド アミリン突然変異タンパク質
WO1994018571A1 (en) * 1993-02-12 1994-08-18 Amylin Pharmaceuticals, Inc. Mcf-7 binding site assays
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
FR2729855A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
EP0907631B1 (de) 1996-05-01 2003-06-18 Nps Pharmaceuticals, Inc. Verbindungen , die auf anorganische ionen-rezeptoren wirken
CN1296384C (zh) * 1999-06-18 2007-01-24 普罗特米克斯发现有限公司 具有preptin功能的肽
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
RU2537181C2 (ru) 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
KR20120011667A (ko) * 2010-07-29 2012-02-08 광주과학기술원 당뇨병 치료제의 스크리닝 방법
KR101271218B1 (ko) * 2012-12-07 2013-06-07 광주과학기술원 당뇨병 치료제의 스크리닝 방법
SG10201906172XA (en) * 2013-07-03 2019-08-27 Alder Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
US20150191541A1 (en) * 2013-12-06 2015-07-09 Neotope Biosciences Limited Antibodies that recognize iapp
EP3083941B1 (de) * 2013-12-16 2023-02-22 Fresenius Medical Care Deutschland GmbH Pankreasinselähnliche zellstrukturen und verfahren zur herstellung davon
WO2015176017A1 (en) * 2014-05-16 2015-11-19 Salk Institute For Biological Studies Compositions and methods for treating metabolic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049654A (en) * 1986-12-04 1991-09-17 Toyo Jozo Kabushiki Kaisha Calcitonin gene related peptide derivatives
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides

Also Published As

Publication number Publication date
DE68924372D1 (de) 1995-11-02
EP0348490B1 (de) 1995-09-27
JPH10267914A (ja) 1998-10-09
WO1989006135A1 (en) 1989-07-13
HK1002990A1 (en) 1998-09-30
DK443889A (da) 1989-10-27
FI894255A0 (fi) 1989-09-08
DK443889D0 (da) 1989-09-08
AU631112B2 (en) 1992-11-19
EP0348490A1 (de) 1990-01-03
FI894255A7 (fi) 1989-09-08
DE68924372T2 (de) 1996-05-09
AU2949489A (en) 1989-08-01
EP0348490A4 (en) 1992-08-12

Similar Documents

Publication Publication Date Title
ATE128359T1 (de) Behandlung von diabetes mellitus typ 2.
Orth et al. Biologic and immunologic characterization and physical separation of ACTH and ACTH fragments in the ectopic ACTH syndrome
Taylor et al. Syndromes of Autoimmunity and Hypoglycemia: Autoantibodies Directed Against insulinand Its Receptor
Valverde et al. Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs
Rudolf et al. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
Abounader et al. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226
Pittner et al. Molecular physiology of amylin
Luft et al. Somatostatin—both hormone and neurotransmitter?
REUBI et al. Specific high affinity binding sites for somatostatin-28 on pancreatic 6-cells: Differences with brain somatostatin receptors
Seidah et al. Complete amino acid sequence of human seminal plasma β‐inhibin: Prediction of post Gln‐Arg cleavage as a maturation site
Morgan et al. Purification and characterization of the receptor for insulin-like growth factor I
Wang et al. Evidence of a paracrine role of neuropeptide-Y in the regulation of insulin release from pancreatic islets of normal and dexamethasone-treated rats
Chejfec et al. Synaptophysin: a new marker for pancreatic neuroendocrine tumors
Mikkelsen et al. Substance P in the median eminence and pituitary of the rat: demonstration of immunoreactive fibers and specific binding sites
PT835266E (pt) Superantigenios modificados / quimericos e seu uso
Maurer et al. Somatostatin receptors in the adrenal
Goltzman et al. Metabolism and biological activity of parathyroid hormone in renal cortical membranes.
Bordi et al. Immunofluorescence, histochemical and ultrastructural studies for the detection of multiple endocrine polypeptide tumours of the pancreas
KOIDA et al. Abundance and location of 125-I-salmon calcitonin binding site in rat brain
CHU et al. Interaction of parathyroid hormone with membranes of kidney cortex: Degradation of the hormone and activation of adenylate cyclase
Gray et al. Proinsulin in human serum: problems in measurement and interpretation
Bordi et al. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide
Connors et al. Dynamics and regulation of TSH secretion by superfused anterior pituitary cells
Inoue et al. Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas
Poitras et al. Motilin synthetic analogues and motilin receptor antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time